Developer docs
API playgroundTry for free, no card

Search company profiles

Sen-Jam Pharmaceutical

Full company profile

uuid00046cc

Namestring
Sen-Jam Pharmaceutical
Legal namestring
Sen-Jam Pharmaceutical
Websiteurl
sen-jam.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Sen-Jam Pharmaceutical is a clinical-stage, computational drug discovery and development company founded in 2014 and headquartered at 223 Wall Street #130, Huntington, NY. The company develops prevention-led combination anti-inflammatory therapeutics targeting large unmet needs across hangover prevention, COVID-19, viral respiratory infections, vaccine side effects, arthritis, opioid use disorder (withdrawal, dependence, and tolerance), metabolic health (MASH/obesity), critical care inflammatory rescue, and longevity/inflammaging. Its pipeline spans more than ten candidates (SJP-001 through SJP-007, plus SJP-100, SJP-200, SJP-101, SJP-002X, and SJP-001X), with lead asset SJP-001 (alcohol hangover prevention, OTC) Phase 3 ready and SJP-002C (COVID-19 treatment, Rx) in Phase II trials.

The company operates through its proprietary Inflammation Atlas platform, an AI-driven Quantitative Systems Pharmaco-Biology engine that maps inflammatory architecture, models feedforward inflammatory loops, identifies molecular nodes, and predicts combination therapeutics. Combinations use AI-matched, already FDA-cleared small molecules with complementary, non-redundant pathway activity targeting COX-Prostaglandin and Histamine/Mast Cell/Adaptive Immune loops, intended to lower regulatory risk by repurposing approved agents. A cross-program NLR (Neutrophil-to-Lymphocyte Ratio) biomarker patent has been filed and validated across two independent Phase 2 datasets, with reported outcomes including a 76% reduction in headache severity and near-complete symptom resolution for SJP-001, and complete symptom clearance by Day 15 for SJP-002C.

Sen-Jam is pre-revenue with a 1-10 person team and pursues a dual-track go-to-market: enterprise out-licensing and co-development partnerships with pharmaceutical companies for global commercialization upon regulatory approval, plus future OTC distribution for consumer products such as SJP-001 and SJP-003. Capital has been raised via equity crowdfunding on StartEngine (approximately $1.0M in 2021 and ~$297K Series A in 2022), a 2025 strategic investment from 5 Horizons Capital, and a notable CRO equity arrangement with TASK Clinical funding two-thirds of the SJP-001 Phase 3 trial. Operational geographies span the US (headquarters), Australia (Novotech-led Phase 2), and Canada (Cliantha Research Phase 2), with clinical and CMC execution supported by partners TASK Clinical, KVK Tech, Cliantha Research, and Novotech.

Short descriptiontext

Sen-Jam Pharmaceutical is a clinical-stage drug discovery company using its proprietary Inflammation Atlas AI platform to develop combination anti-inflammatory therapeutics. Its pipeline includes a Phase 3-ready hangover prevention OTC, a Phase II COVID-19 treatment, and opioid, metabolic, and longevity programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHuntington, United States
HQ citystring
Huntington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anti-inflammatory therapeutics, computational drug discovery, combination drug therapy, clinical stage biopharmaceutical, inflammation drug pipeline
Industry4 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Anti-Inflammatory Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Equity Funding / Crowdfunding
TypeOne Time License
Description

The company launched a Series A funding round through the StartEngine crowdfunding platform, engaging private and institutional investors to support drug portfolio advancement. The company has also secured strategic investments from financial partners including 5 Horizons Capital and equity arrangements with CRO partners.

prnewswire.com
2Licensing Royalties
TypeLicensing Royalties
Description

Revenue expected from licensing deals for drug candidates upon successful clinical trials and regulatory approvals. The company is building toward global licensing discussions ahead of pivotal Phase 3 programs.

prnewswire.com
3Pharmaceutical Product Sales (Future)
TypeOne Time License
Description

Once products receive regulatory approval, revenue anticipated from OTC and prescription pharmaceutical product sales including SJP-001 (hangover), SJP-002C (COVID), and pipeline assets for opioid addiction, arthritis, and metabolic health.

prnewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sen-Jam Pharmaceutical develops a portfolio of combination therapeutic drug candidates for inflammatory conditions, generated through its proprietary AI-driven Inflammation Atlas platform. Its lead asset, SJP-001 (hangover prevention), is Phase 3 ready with a 76% reduction in headache severity demonstrated in clinical studies; SJP-002C (COVID-19 treatment) is in Phase II; additional pipeline assets address viral respiratory infections, vaccine side effects, arthritis, opioid withdrawal/dependence/tolerance, metabolic health, MASH, critical care inflammation, longevity, and enteropathic arthritis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 76% reduction in headache severity with SJP-001
+5 more records
Product overview1 text field

Sen-Jam Pharmaceutical is a computational drug discovery and development company pioneering a prevention-led therapeutic platform focused on inflammatory resolution. The company operates through its proprietary Inflammation Atlas—an AI-driven systems biology engine that maps inflammatory architecture and generates combination therapeutics. The core portfolio includes multiple clinical-stage and preclinical drug candidates across therapeutic areas: SJP-001 (alcohol hangover prevention, Phase 3 ready, OTC), SJP-002C (COVID-19 treatment, Phase II, Rx), SJP-002 (viral respiratory infections, OTC), SJP-003 (vaccine side effects), SJP-004 (arthritis, Rx), SJP-005/006/007 (opioid use disorder addressing withdrawal, dependence, and tolerance respectively, Rx), plus pipeline assets including SJP-100 (critical care injectable), SJP-002X/001X (metabolic health), SJP-200 (longevity), and SJP-101 (enteropathic arthritis). The company emphasizes earlier intervention through immune balance restoration without immunosuppression, with clinical validation demonstrated across two independent Phase 2 programs.

Product and service14 records
1Inflammation Atlas
CategoryDrug Discovery Platform / Technology
Description

Proprietary AI-driven Quantitative Systems Pharmaco-Biology engine that maps human inflammatory architecture, models feedforward inflammatory loops, identifies molecular nodes driving them, and predicts combination therapeutics designed for earlier, safer, and more complete inflammatory resolution. Used internally to generate Sen-Jam's SJP pipeline candidates.

2SJP-001 (Alcohol Hangover Prevention)
CategoryOTC Therapeutic - Inflammation / Pain
Description

Over-the-counter oral combination therapeutic targeting COX-Prostaglandin and Histamine loops for prevention of alcohol hangover (veisalgia). Phase 3 ready with 76% reduction in headache severity and near-complete symptom resolution demonstrated in human studies; positioned as the only FDA-approved agent in development for this indication.

3SJP-002C (COVID-19 Treatment)
CategoryPrescription Therapeutic - Antiviral/Anti-inflammatory
Description

Prescription-strength oral anti-inflammatory therapeutic for treatment of SARS-CoV-2 infection, targeting COX-Prostaglandin, Mast Cell, and Adaptive Immune loops. In Phase II clinical trials with complete symptom clearance by Day 15 and selective immune rebalancing demonstrated.

4SJP-002 (Viral Respiratory Infections, OTC)
CategoryOTC Therapeutic - Anti-inflammatory
Description

Over-the-counter oral therapeutic for symptoms associated with viral respiratory infections including coronaviruses and the common cold, reducing excessive inflammatory response that causes congestion, coughing, sneezing, and headache.

5SJP-003 (Vaccine Side-Effect Reduction)
CategoryOTC Therapeutic - Anti-inflammatory
Description

Over-the-counter oral therapeutic administered at the time of vaccination to reduce or eliminate common vaccine administration side effects such as sore arm and low-grade fever.

6SJP-004 (Arthritis)
CategoryPrescription Therapeutic - Inflammation / Pain
Description

Prescription-strength oral therapeutic designed to address inflammation and aches associated with arthritis without the side-effect profile of opioid-based agents.

7SJP-005 (Opioid Withdrawal)
CategoryPrescription Therapeutic - Addiction Medicine
Description

Prescription-strength oral therapeutic for opioid use disorder that reduces signs and symptoms of withdrawal by 50% in pre-clinical studies, addressing a critical factor in combating the opioid epidemic.

8SJP-006 (Opioid Dependence)
CategoryPrescription Therapeutic - Addiction Medicine
Description

Prescription-strength oral therapeutic designed to address opioid dependence, making tapering off opioid pain killers more readily available for the millions of patients prescribed opioids each year.

9SJP-007 (Opioid Tolerance)
CategoryPrescription Therapeutic - Addiction Medicine
Description

Prescription-strength oral therapeutic that helps lower individual tolerance factors to opioids including OxyContin, morphine, oxycodone, and heroin, supporting reversal of opioid dependence.

10SJP-100 (Inflammatory Rescue Program)
CategoryPrescription Therapeutic - Critical Care
Description

Prescription-strength injectable therapeutic for inflammatory rescue programs in critical care settings.

11SJP-002X (Obesity / MASH)
CategoryPrescription Therapeutic - Metabolic Disease
Description

Prescription-strength oral therapeutic targeting obesity and MASH (Metabolic dysfunction-associated steatohepatitis) for metabolic health.

12SJP-001X (Metabolic Recovery)
CategoryOTC Therapeutic - Metabolic Health
Description

Over-the-counter oral therapeutic for metabolic recovery targeting metabolic health and weight management.

13SJP-200 (Healthy Aging / Longevity)
CategoryPrescription Therapeutic - Longevity / Healthy Aging
Description

Prescription-strength oral therapeutic targeting inflammaging and low-grade chronic inflammatory conditions associated with healthy aging and longevity.

14SJP-101 (Enteropathic Arthritis)
CategoryPrescription Therapeutic - Inflammatory Disease
Description

Prescription-strength injectable therapeutic for enteropathic arthritis, a chronic inflammatory disease.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1TASK Clinical
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with TASK Clinical, a global contract research organization (CRO), under which TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity. This rare arrangement where a CRO takes an equity position in sponsor trials significantly de-risks the pivotal program and strengthens investor confidence and licensing opportunities.

finance.yahoo.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Corporate venture partner handling formulation, CMC (Chemistry, Manufacturing and Controls), and FDA submission readiness. Forms part of the vertically integrated development ecosystem for Sen-Jam's drug candidates.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical CRO with expertise in early-phase trials, conducting Phase 2 trial of SJP-001 with ethics approval obtained in Australia. Partnership aims to advance development and potential global adoption.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Phase 2 trial conducted by Cliantha Research in Toronto, completed in November with data readout expected in Q1 2026.

Strategic tierMinorTypeOthers
Description

Appointed as Executive Advisor to support commercialization strategy and pipeline development, guiding strategic planning, partner exploration, and launch preparedness for anti-inflammatory therapeutics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Computational drug discovery platform company combining physics-based simulation with AI for therapeutic discovery across multiple partners. Comparable through its AI/computational platform approach to inflammatory and other targets, though substantially larger and software-plus-collaboration oriented.

TypeDirect peer
Description

Clinical-stage biotech developing oral therapeutics for inflammatory and autoimmune diseases (ulcerative colitis, Crohn's). Comparable as a clinical-stage inflammation company with a similar small-team, outsourced-execution model and reliance on licensing for global commercialization.

TypeDirect peer
Description

Clinical-stage AI-driven drug discovery company combining computational biology with experimental validation across multiple therapeutic areas. Highly comparable to Sen-Jam's Inflammation Atlas platform approach and pipeline breadth, though operating at significantly larger scale and capital base.

TypeDirect peer
Description

Clinical-stage CNS-focused biotech developing anti-inflammatory and novel mechanism therapeutics (e.g., Auvelity for depression, migraine products). Comparable as a small-cap, clinical-stage inflammation/CNS company pursuing differentiated mechanisms with similar regulatory and licensing pathway dynamics.

5Morphic Holding
TypeDirect peer
Description

Clinical-stage biotech developing oral integrin inhibitors for inflammatory and autoimmune diseases. Comparable as a clinical-stage inflammation company pursuing differentiated oral small-molecule approaches with similar regulatory and competitive dynamics.

TypeDirect peer
Description

Clinical-stage biotech developing novel therapeutics for inflammatory and immunological diseases, including dermatology indications. Comparable in therapeutic area overlap (inflammation) and stage profile, with similar strategic optionality around licensing and combination development.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics targeting the biology of aging, including metabolic and inflammatory pathways. Closely comparable in the inflammaging/longevity space Sen-Jam targets via SJP-200 and SJP-001X/002X, with similar capital needs and clinical-stage profile.

TypeDirect peer
Description

Clinical-stage biotech developing transformative treatments for hematological and musculoskeletal disorders with inflammatory drivers. Comparable as a small-cap clinical-stage inflammation/biologics company with similar capital needs and licensing-driven business model.

TypeDirect peer
Description

Clinical-stage biotech developing novel therapies for fibrotic and inflammatory diseases using integrin-based mechanisms. Comparable as a clinical-stage inflammation company with multiple pipeline assets and similar strategic positioning for licensing transactions.

TypeEmerging player
Description

AI-driven drug discovery company combining machine learning with high-throughput biology to develop therapeutics. Comparable through its computational platform approach to inflammatory and metabolic diseases, though operating at a larger capital base and more diverse partnership model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sen-Jam Pharmaceutical

Anti-Inflammatory Pharmaceuticalssen-jam.com

Sen-Jam Pharmaceutical is a clinical-stage drug discovery company using its proprietary Inflammation Atlas AI platform to develop combination anti-inflammatory therapeutics. Its pipeline includes a Phase 3-ready hangover prevention OTC, a Phase II COVID-19 treatment, and opioid, metabolic, and longevity programs.

What Sen-Jam Pharmaceutical does

Sen-Jam Pharmaceutical is a clinical-stage, computational drug discovery and development company founded in 2014 and headquartered at 223 Wall Street #130, Huntington, NY. The company develops prevention-led combination anti-inflammatory therapeutics targeting large unmet needs across hangover prevention, COVID-19, viral respiratory infections, vaccine side effects, arthritis, opioid use disorder (withdrawal, dependence, and tolerance), metabolic health (MASH/obesity), critical care inflammatory rescue, and longevity/inflammaging. Its pipeline spans more than ten candidates (SJP-001 through SJP-007, plus SJP-100, SJP-200, SJP-101, SJP-002X, and SJP-001X), with lead asset SJP-001 (alcohol hangover prevention, OTC) Phase 3 ready and SJP-002C (COVID-19 treatment, Rx) in Phase II trials.

The company operates through its proprietary Inflammation Atlas platform, an AI-driven Quantitative Systems Pharmaco-Biology engine that maps inflammatory architecture, models feedforward inflammatory loops, identifies molecular nodes, and predicts combination therapeutics. Combinations use AI-matched, already FDA-cleared small molecules with complementary, non-redundant pathway activity targeting COX-Prostaglandin and Histamine/Mast Cell/Adaptive Immune loops, intended to lower regulatory risk by repurposing approved agents. A cross-program NLR (Neutrophil-to-Lymphocyte Ratio) biomarker patent has been filed and validated across two independent Phase 2 datasets, with reported outcomes including a 76% reduction in headache severity and near-complete symptom resolution for SJP-001, and complete symptom clearance by Day 15 for SJP-002C.

Sen-Jam is pre-revenue with a 1-10 person team and pursues a dual-track go-to-market: enterprise out-licensing and co-development partnerships with pharmaceutical companies for global commercialization upon regulatory approval, plus future OTC distribution for consumer products such as SJP-001 and SJP-003. Capital has been raised via equity crowdfunding on StartEngine (approximately $1.0M in 2021 and ~$297K Series A in 2022), a 2025 strategic investment from 5 Horizons Capital, and a notable CRO equity arrangement with TASK Clinical funding two-thirds of the SJP-001 Phase 3 trial. Operational geographies span the US (headquarters), Australia (Novotech-led Phase 2), and Canada (Cliantha Research Phase 2), with clinical and CMC execution supported by partners TASK Clinical, KVK Tech, Cliantha Research, and Novotech.

Sen-Jam Pharmaceutical firmographics

Firmographics
Name
Sen-Jam Pharmaceutical
Legal name
Sen-Jam Pharmaceutical
Website
https://sen-jam.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Sen-Jam Pharmaceutical is a clinical-stage drug discovery company using its proprietary Inflammation Atlas AI platform to develop combination anti-inflammatory therapeutics. Its pipeline includes a Phase 3-ready hangover prevention OTC, a Phase II COVID-19 treatment, and opioid, metabolic, and longevity programs.
Ownership category
akta.pro rank

Sen-Jam Pharmaceutical industry classification

Industry
Product category
Anti-Inflammatory Pharmaceuticals
NAICS
Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Anti-inflammatory therapeutics
  • Computational drug discovery
  • Combination drug therapy
  • Clinical stage biopharmaceutical
  • Inflammation drug pipeline

Where Sen-Jam Pharmaceutical is headquartered

Location

Headquarters

HQ city
Huntington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sen-Jam Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Equity Funding / Crowdfunding: The company launched a Series A funding round through the StartEngine crowdfunding platform, engaging private and institutional investors to support drug portfolio advancement. The company has also secured strategic investments from financial partners including 5 Horizons Capital and equity arrangements with CRO partners.
  2. Licensing Royalties: Revenue expected from licensing deals for drug candidates upon successful clinical trials and regulatory approvals. The company is building toward global licensing discussions ahead of pivotal Phase 3 programs.
  3. Pharmaceutical Product Sales (Future): Once products receive regulatory approval, revenue anticipated from OTC and prescription pharmaceutical product sales including SJP-001 (hangover), SJP-002C (COVID), and pipeline assets for opioid addiction, arthritis, and metabolic health.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Sen-Jam Pharmaceutical product offering

Product offering

Core offering

Sen-Jam Pharmaceutical develops a portfolio of combination therapeutic drug candidates for inflammatory conditions, generated through its proprietary AI-driven Inflammation Atlas platform. Its lead asset, SJP-001 (hangover prevention), is Phase 3 ready with a 76% reduction in headache severity demonstrated in clinical studies; SJP-002C (COVID-19 treatment) is in Phase II; additional pipeline assets address viral respiratory infections, vaccine side effects, arthritis, opioid withdrawal/dependence/tolerance, metabolic health, MASH, critical care inflammation, longevity, and enteropathic arthritis.

Product overview

Sen-Jam Pharmaceutical is a computational drug discovery and development company pioneering a prevention-led therapeutic platform focused on inflammatory resolution. The company operates through its proprietary Inflammation Atlas—an AI-driven systems biology engine that maps inflammatory architecture and generates combination therapeutics. The core portfolio includes multiple clinical-stage and preclinical drug candidates across therapeutic areas: SJP-001 (alcohol hangover prevention, Phase 3 ready, OTC), SJP-002C (COVID-19 treatment, Phase II, Rx), SJP-002 (viral respiratory infections, OTC), SJP-003 (vaccine side effects), SJP-004 (arthritis, Rx), SJP-005/006/007 (opioid use disorder addressing withdrawal, dependence, and tolerance respectively, Rx), plus pipeline assets including SJP-100 (critical care injectable), SJP-002X/001X (metabolic health), SJP-200 (longevity), and SJP-101 (enteropathic arthritis). The company emphasizes earlier intervention through immune balance restoration without immunosuppression, with clinical validation demonstrated across two independent Phase 2 programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Inflammation Atlas Proprietary AI-driven Quantitative Systems Pharmaco-Biology engine that maps human inflammatory architecture, models feedforward inflammatory loops, identifies molecular nodes driving them, and predicts combination therapeutics designed for earlier, safer, and more complete inflammatory resolution. Used internally to generate Sen-Jam's SJP pipeline candidates.
  • SJP-001 (Alcohol Hangover Prevention) Over-the-counter oral combination therapeutic targeting COX-Prostaglandin and Histamine loops for prevention of alcohol hangover (veisalgia). Phase 3 ready with 76% reduction in headache severity and near-complete symptom resolution demonstrated in human studies; positioned as the only FDA-approved agent in development for this indication.
  • SJP-002C (COVID-19 Treatment) Prescription-strength oral anti-inflammatory therapeutic for treatment of SARS-CoV-2 infection, targeting COX-Prostaglandin, Mast Cell, and Adaptive Immune loops. In Phase II clinical trials with complete symptom clearance by Day 15 and selective immune rebalancing demonstrated.
  • SJP-002 (Viral Respiratory Infections, OTC) Over-the-counter oral therapeutic for symptoms associated with viral respiratory infections including coronaviruses and the common cold, reducing excessive inflammatory response that causes congestion, coughing, sneezing, and headache.
  • SJP-003 (Vaccine Side-Effect Reduction) Over-the-counter oral therapeutic administered at the time of vaccination to reduce or eliminate common vaccine administration side effects such as sore arm and low-grade fever.
  • SJP-004 (Arthritis) Prescription-strength oral therapeutic designed to address inflammation and aches associated with arthritis without the side-effect profile of opioid-based agents.
  • SJP-005 (Opioid Withdrawal) Prescription-strength oral therapeutic for opioid use disorder that reduces signs and symptoms of withdrawal by 50% in pre-clinical studies, addressing a critical factor in combating the opioid epidemic.
  • SJP-006 (Opioid Dependence) Prescription-strength oral therapeutic designed to address opioid dependence, making tapering off opioid pain killers more readily available for the millions of patients prescribed opioids each year.
  • SJP-007 (Opioid Tolerance) Prescription-strength oral therapeutic that helps lower individual tolerance factors to opioids including OxyContin, morphine, oxycodone, and heroin, supporting reversal of opioid dependence.
  • SJP-100 (Inflammatory Rescue Program) Prescription-strength injectable therapeutic for inflammatory rescue programs in critical care settings.
  • SJP-002X (Obesity / MASH) Prescription-strength oral therapeutic targeting obesity and MASH (Metabolic dysfunction-associated steatohepatitis) for metabolic health.
  • SJP-001X (Metabolic Recovery) Over-the-counter oral therapeutic for metabolic recovery targeting metabolic health and weight management.
  • SJP-200 (Healthy Aging / Longevity) Prescription-strength oral therapeutic targeting inflammaging and low-grade chronic inflammatory conditions associated with healthy aging and longevity.
  • SJP-101 (Enteropathic Arthritis) Prescription-strength injectable therapeutic for enteropathic arthritis, a chronic inflammatory disease.

Quantifiable outcome

  • 76% reduction in headache severity with SJP-001
  • +5 more outcomes

Companies that use Sen-Jam Pharmaceutical

Customer profile

Segments4 records

Ideal customer profiles2 records

Sen-Jam Pharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Sen-Jam Pharmaceutical partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • TASK ClinicalcoreStrategic or Co-development PartnerStrategic partnership with TASK Clinical, a global contract research organization (CRO), under which TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity. This rare arrangement where a CRO takes an equity position in sponsor trials significantly de-risks the pivotal program and strengthens investor confidence and licensing opportunities.
  • KVK TechcoreStrategic or Co-development PartnerCorporate venture partner handling formulation, CMC (Chemistry, Manufacturing and Controls), and FDA submission readiness. Forms part of the vertically integrated development ecosystem for Sen-Jam's drug candidates.
  • NovotechcoreStrategic or Co-development PartnerClinical CRO with expertise in early-phase trials, conducting Phase 2 trial of SJP-001 with ethics approval obtained in Australia. Partnership aims to advance development and potential global adoption.
  • Cliantha ResearchcoreStrategic or Co-development PartnerPhase 2 trial conducted by Cliantha Research in Toronto, completed in November with data readout expected in Q1 2026.
  • Rute FernandesminorOthersAppointed as Executive Advisor to support commercialization strategy and pipeline development, guiding strategic planning, partner exploration, and launch preparedness for anti-inflammatory therapeutics.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Sen-Jam Pharmaceutical competitors and assessment

Company assessment

Broad incumbents

  • Schrödinger, Inc. Computational drug discovery platform company combining physics-based simulation with AI for therapeutic discovery across multiple partners. Comparable through its AI/computational platform approach to inflammatory and other targets, though substantially larger and software-plus-collaboration oriented.

Direct peers

  • Landos Biopharma: Clinical-stage biotech developing oral therapeutics for inflammatory and autoimmune diseases (ulcerative colitis, Crohn's). Comparable as a clinical-stage inflammation company with a similar small-team, outsourced-execution model and reliance on licensing for global commercialization.
  • Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining computational biology with experimental validation across multiple therapeutic areas. Highly comparable to Sen-Jam's Inflammation Atlas platform approach and pipeline breadth, though operating at significantly larger scale and capital base.
  • Axsome Therapeutics: Clinical-stage CNS-focused biotech developing anti-inflammatory and novel mechanism therapeutics (e.g., Auvelity for depression, migraine products). Comparable as a small-cap, clinical-stage inflammation/CNS company pursuing differentiated mechanisms with similar regulatory and licensing pathway dynamics.
  • Morphic Holding: Clinical-stage biotech developing oral integrin inhibitors for inflammatory and autoimmune diseases. Comparable as a clinical-stage inflammation company pursuing differentiated oral small-molecule approaches with similar regulatory and competitive dynamics.
  • Aclaris Therapeutics: Clinical-stage biotech developing novel therapeutics for inflammatory and immunological diseases, including dermatology indications. Comparable in therapeutic area overlap (inflammation) and stage profile, with similar strategic optionality around licensing and combination development.
  • BioAge Labs: Clinical-stage biotech developing therapeutics targeting the biology of aging, including metabolic and inflammatory pathways. Closely comparable in the inflammaging/longevity space Sen-Jam targets via SJP-200 and SJP-001X/002X, with similar capital needs and clinical-stage profile.
  • Keros Therapeutics: Clinical-stage biotech developing transformative treatments for hematological and musculoskeletal disorders with inflammatory drivers. Comparable as a small-cap clinical-stage inflammation/biologics company with similar capital needs and licensing-driven business model.
  • Pliant Therapeutics: Clinical-stage biotech developing novel therapies for fibrotic and inflammatory diseases using integrin-based mechanisms. Comparable as a clinical-stage inflammation company with multiple pipeline assets and similar strategic positioning for licensing transactions.

Emerging players

  • Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to develop therapeutics. Comparable through its computational platform approach to inflammatory and metabolic diseases, though operating at a larger capital base and more diverse partnership model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Sen-Jam Pharmaceutical social profiles

Digital presence

Sen-Jam Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sen-Jam Pharmaceutical leadership team

Management profile

Number of profiles

Profiles11 records

Sen-Jam Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sen-Jam Pharmaceutical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sen-Jam Pharmaceutical

What does Sen-Jam Pharmaceutical do?

Sen-Jam Pharmaceutical develops a portfolio of combination therapeutic drug candidates for inflammatory conditions, generated through its proprietary AI-driven Inflammation Atlas platform. Its lead asset, SJP-001 (hangover prevention), is Phase 3 ready with a 76% reduction in headache severity demonstrated in clinical studies; SJP-002C (COVID-19 treatment) is in Phase II; additional pipeline assets address viral respiratory infections, vaccine side effects, arthritis, opioid withdrawal/dependence/tolerance, metabolic health, MASH, critical care inflammation, longevity, and enteropathic arthritis.

Is Sen-Jam Pharmaceutical a public or private company?

Sen-Jam Pharmaceutical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sen-Jam Pharmaceutical founded?

Sen-Jam Pharmaceutical was founded in 2017. It employs 11 to 50 people.

Where is Sen-Jam Pharmaceutical based?

Sen-Jam Pharmaceutical is headquartered in Huntington, United States, in the North America region.

How does Sen-Jam Pharmaceutical make money?

Three revenue lines are on record. Equity Funding / Crowdfunding is the primary driver. The others are licensing Royalties and pharmaceutical Product Sales (Future).

Who are Sen-Jam Pharmaceutical's main competitors?

Schrödinger, Inc. is listed as a broad incumbent. Direct peers are Landos Biopharma, Recursion Pharmaceuticals, Axsome Therapeutics, Morphic Holding, Aclaris Therapeutics, BioAge Labs, Keros Therapeutics and Pliant Therapeutics. Insitro is listed as an emerging player.

Does Sen-Jam Pharmaceutical have an API?

No public API is recorded for Sen-Jam Pharmaceutical.

What industry is Sen-Jam Pharmaceutical in?

Sen-Jam Pharmaceutical's product category is Anti-Inflammatory Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmacy TimesAlcohol Hangover is Classified as a Disease: What Does That Mean For Treating Hangovers Therapeutically?The International Classification of Diseases 11th Revision (ICD-11) has officially classified alcohol hangover as a disease, a move that aligns with FDA regulations requiring such treatments to be registered as drugs rather than dietary supplements. This classification invalidates current market claims for over 80 existing hangover supplements and prompts regulatory warnings against unauthorized disease modification claims. Concurrently, Sen-Jam Pharmaceutical is advancing its investigational drug SJP-001 through clinical trials to provide an evidence-based therapeutic option targeting the inflammatory response associated with hangovers.YouTubeJim Iversen, Sen-Jam Pharmaceutical | theCUBE + NYSE Wired: AI in BioJim Iversen, CEO of Sen-Jam Pharmaceutical, discussed AI's role in drug discovery and clinical development, detailing the company's three-layer Galaxy platform. The platform validated previously shelved assets with a 200% to 300% higher probability of success. Iversen also outlined a phase three study on alcohol's impact on inflammaging and results reducing opioid withdrawal severity by 50%.YahooSen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001Sen-Jam Pharmaceutical announced a strategic partnership with TASK Clinical, a global contract research organization, under which TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity, significantly de-risking the pivotal program. The deal is described as exceptionally rare, as CROs taking equity positions in sponsor trials is uncommon, and is expected to strengthen investor confidence and licensing opportunities. The partnership complements existing relationships with manufacturing partner KVK Tech and Executive Advisor Rute Fernandes to accelerate the company's path toward regulatory filing and commercialization.PR NewswireSen-Jam Pharmaceutical Secures Major Strategic Partnership with TASK Clinical to Fund Two-Thirds of Phase 3 Trial for SJP-001Sen-Jam Pharmaceutical announced a strategic partnership with TASK Clinical, a global contract research organization, under which TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 (a hangover-prevention therapeutic) in exchange for equity, a rare arrangement that significantly de-risks development and enhances investor confidence. The company has also established a vertically integrated development ecosystem including KVK Tech as its corporate venture partner handling formulation, CMC, and FDA submission readiness, with the Phase 2 trial conducted by Cliantha Research in Toronto completed in November and data readout expected in Q1 2026. This partnership positions Sen-Jam for accelerated investor engagement and global licensing discussions ahead of the pivotal Phase 3 program.PR NewswireSen-Jam Pharmaceutical Advances First-in-Class FDA Hangover Prevention Therapy, SJP-001, to Phase 2 Trials in CanadaSen-Jam Pharmaceutical has initiated a Phase 2 clinical trial in Canada for its hangover prevention therapy SJP-001, in partnership with research organization Cliantha Research. The therapy targets the inflammatory root cause of alcohol-induced symptoms and aims to become the first FDA-approved hangover treatment, representing a first-in-class approach supported by 23 global patents. The global hangover remedies market is projected to grow to $6.2 billion by 2030 at a 14.9% CAGR, reflecting growing clinical and investor interest in evidence-based inflammation-targeted solutions.citybizSen-Jam Pharmaceutical Secures Financial and Strategic Investment from 5 Horizons CapitalSen-Jam Pharmaceutical secured financial and strategic investment from 5 Horizons Capital, which will lead the Phase 2 clinical trial of SJP-001. The trial, recently approved in Australia, evaluates the drug's efficacy in mitigating inflammation and promoting metabolic health. The company is seeking follow-on investments to accelerate development.FinSMEsSen-Jam Pharmaceutical Receives Investment from 5 Horizons CapitalSen-Jam Pharmaceutical, a NYC-based biotech targeting inflammation and metabolic health, received an undisclosed investment from 5 Horizons Capital. The company will use the funds to deliver scalable solutions and advance its PAIR technology. CEO Jim Iversen said the investment brings SJP-001 closer to patients.YahooSen-Jam Pharmaceutical Secures Financial and Strategic Investment from 5 Horizons Capital to Advance SJP-001 Clinical Trial with NovotechSen-Jam Pharmaceutical secured financial and strategic investment from 5 Horizons Capital to advance its SJP-001 Phase 2 clinical trial with Novotech. The trial, recently approved in Australia, evaluates the drug's efficacy in mitigating inflammation and promoting metabolic health. 5 Horizons will seek follow-on investments to accelerate development.PR NewswireSen-Jam Pharmaceutical Secures Financial and Strategic Investment from 5 Horizons Capital to Advance SJP-001 Clinical Trial with NovotechSen-Jam Pharmaceutical announced a financial and strategic investment from 5 Horizons Capital to advance its SJP-001 Phase 2 clinical trial with Novotech. The trial, recently approved in Australia, evaluates the drug's efficacy for inflammation and metabolic health. 5 Horizons will seek follow-on investments to accelerate development.Clinical Trials ArenaSen-Jam reports positive outcomes from Phase II trial of Covid-19 therapeuticSen-Jam Pharmaceutical reported positive preliminary outcomes from its Phase II trial of SJP-002C, a therapeutic for upper respiratory infections including Covid-19, citing an exceptional safety profile and early symptom improvement. The company is currently examining further clinical data to confirm statistical significance and is considering additional studies to broaden the therapy's application. Additionally, Sen-Jam recently received ethics approval in Australia for a separate clinical trial of its lead asset SJP-001.